The goal of this submission is to describe how and when to best use hemostats, sealants, and adhesives as well as to compare their characteristics and to update the surgical toolbox with respect to any new products approved by the Food and Drug Administration (FDA) as of this date (November 2009). The materials will be presented in 3 major groups each containing specific categories: (1) hemostats; mechanical, active, flowable, and fibrin sealant, (2) sealants; fibrin sealant, polyethylene glycol polymer, and albumin and glutaraldehyde, (3) adhesives; cyanoacrylate, albumin and glutaraldehyde, and fibrin sealant. The categories will be used for comparisons based on safety, efficacy, usability, and cost. Recommendations with respect to how and when to best use these materials will be presented. A review of the recent literature is also provided with respect to the most recent uses of these materials in specific surgical specialties.
Introduction
As the challenges facing surgeons in the 21st century increase, knowledge of the available components for the surgical toolbox, 1 which can assist in the technical performance of an operation becomes more important. The demands for smaller more minimally invasive procedures, 2 reduced use of transfusions, 3 and reduced costs 4 create greater hurdles than ever for today's practicing surgeon. Hemostats, sealants, and adhesives are components of the surgical toolbox, which may help manage these challenges. 1 Surgery is a branch of medicine in which knowledge, judgment, clinical experience, and technical skill are required for success. Training in medical school and residency facilitates development of these talents for surgeons. During this educational process, significant time is spent in mastering each of the required elements including the ability to meticulously cut and carefully sew. The goal of this review is to enhance these skills by increasing knowledge with respect to some of the surgical adjuncts that may enhance the performance of operations. This article will not only describe, compare, and contrast the available materials but also emphasize how they are best used.
To most clearly cover this topic, some definitions should be provided. Topical hemostats are materials that stop bleeding by causing blood to clot and thus require blood to be present to satisfy their clotting function. Sealants are agents that can prevent the leakage of potentially nonclotting fluids from tissues such as cerebrospinal fluid (CSF) from the central nervous system but may also be capable of preventing the leakage of blood from blood vessels. Finally, adhesives are glues which are capable of bonding various tissues together including a variety of surfaces such as skin or muscle and are also capable of bonding blood vessels together. It is useful to know in which of these 3 groups a Food and Drug Administration (FDA)Àapproved product (as of November 2009) belongs because this knowledge helps in clarifying how to best use the material. A classification system for these materials based on groups, categories, classes, and products is provided (Figure 1) . This system will be used throughout this review. The categories will be used to present information comparing safety, efficacy, usability, and cost. Generic classes of agents will be used to describe how and when to best use these materials with respect to specific specialties and procedures.
UpDate and Comparison of FDA-Approved Agents Hemostats
The commercial products currently available for use by surgeons in the United States in the hemostat group may be divided into 4 categories ( Figure 2 ) based on their functional characteristics: mechanical, active, flowable, and fibrin sealant.
The materials in the mechanical category act predominantly by forming a barrier to stop the flow of blood as well as by creating a surface on which blood may more rapidly clot. The mechanical category can be further organized into 4 descriptive generic classes ( Figure 2 ): porcine gelatin, bovine collagen, oxidized regenerated cellulose, and polysaccharide spheres. The individual manufacture's products in each class within the mechanical category have been previously presented in detail. 1 Two new brands of polysaccharide spheres (Hemostase MPH, Cryolife; Vitasure, Orthovita; Figure 2 ) are now commercially available in addition to the originally marketed product (Arista AH, Medafor, Minneapolis, Minnesota). 5 The mechanical agents as a class are relatively safe with swelling and infection being 2 notable risks of several listed in their package inserts ( Figure 3) . Thus, the manufacturers recommend removal of mechanical agents if possible after achieving hemostasis. One of the products in the bovine collagen class (Ultrafoam, Johnson & Johnson, Somerville, New Jersey) is suggested to potentially have less risk of collagen fibril swelling due to the use of ethyl alcohol in the manufacturing process, 6 and all products in the oxidized regenerated cellulose class (Surgicel, Surgical Microfibrillar, Surgicel Nu-knit, Johnson & Johnson) are suggested to reduce the risk of infection by creating an acid bactericidal environment. 7 However, this same decrease in pH may inactivate stand-alone thrombins or fibrin sealants containing thrombin when used conjointly with oxidized regenerated cellulose. 7 The mechanical hemostats may be useful for the most minimal bleeding. They may also have some variance in their efficacy. Bovine collagens 8, 9 and polysaccharide spheres 10 may have some advantages in efficacy whereas the function of porcine gelatins may be improved by combination with topical thrombin. 11 A major advantage of mechanical agents is their ease of use or usability. They are immediately available on opening the product's package requiring no special storage, preparation, or reconstitution by operating room personnel. Their application to a bleeding site is straightforward, requiring only direct pressure by the surgeon. These agents are relatively inexpensive, although price premiums may exist for those thought to have particular advantages.
The active hemostat category consists of 3 available standalone forms of thrombin and is differentiated into classes based on the source of the plasma used to create these hemostats ( Figure 2 ). The individual manufacture's products in each class within the active category have been previously presented in detail. 1 Each functions by providing concentrated thrombin capable of rapidly converting fibrinogen into a fibrin clot. The rate of clot formation is proportional to the thrombin concentration. The safety profile of each of the 3 classes, bovine plasma, pooled human plasma, and recombinant, is different ( Figure 3 ), although none of the 3 forms of thrombin should ever be injected intravascularly. Antibody formation associated with the use of bovine thrombin potentially leading to coagulopathy and rarely death has resulted in a black box warning, the FDA's highest level of concern, being placed on the material's package insert. 12 Pooled human plasma thrombin has a potential risk of viral or prion (the agent responsible for Creutzfeldt-Jakob disease) disease transmission due to the multiple units of blood used in manufacturing each lot of product. 13 Genetic engineering used to produce recombinant thrombin reduces the risks of antibody formation and eliminates the risk of known disease transmission. Allergic reactions to hamster or snake proteins used in manufacturer of the recombinant product are listed as potential dangers. 14 The efficacy of all 3 classes of stand-alone thrombin which each contain about 1000 IU/mL is functionally the same. 13, 15 Each is equally effective for local or diffuse bleeding. Bovine thrombin and recombinant thrombin are provided as room temperature lyophilized powders that need reconstitution, 12, 14 whereas the human pooled thrombin is fully mixed but requires thawing prior to prompt use or storage thawed in a refrigerator for no longer than 1 month. 13 These products can be applied locally or sprayed over a large area. The stand-alone thrombins can also be combined with absorbable gelatin sponge [12] [13] [14] to enhance efficacy and ease of application. A kit (Gelfoam Plus, Baxter, Hayward, California) has been recently introduced, which provides a porcine gelatin sponge and a lower concentration of lyophilized human pooled thrombin (125 IU/mL) that does not require refrigeration together in a single package. 16 Finally, the cost of the standalone thrombins is intermediate, but there may be some variation among products within the category based on safety profile differences. 17 The flowable category represents a combination of mechanical materials and thrombin. Thus, these products work by mechanically obstructing the flow of blood and actively converting fibrinogen in blood into fibrin at the site of bleeding. The individual manufacture's products in each class within the flowable category have been previously presented in detail. 1 There are 2 classes in this category ( Figure 2 ). The first consists of a combination of absorbable bovine gelatin particles with pooled human thrombin and the second consists of absorbable porcine gelatin particles that may be combined with any of the 3 stand-alone thrombins described earlier. Recently, the manufacturer of the absorbable gelatin has gained approval to package this originally stand-alone product (Surgiflo, Johnson and Johnson, Somerville, New Jersey) with a form of lyophilized pooled human thrombin (Evithrom, Johnson and Johnson, Somerville, New Jersey) that can be stored at room temperature. The combination may be obtained with a long flexible tip. The safety ( Figure 3 ) concerns of flowables represent those of the mechanical and active groups consisting for the first class predominantly of swelling and viral or prion disease transmission and for the second class of swelling and the risk associated with the particular stand-alone thrombin that is chosen. 17 The flowables are most effective for localized bleeding as they allow for mechanical slowing of blood flow, rapid conversion of fibrinogen into fibrin by the action of thrombin on blood, and thorough coverage of the local wound using a substance that easily conforms to the topography of the underlying tissues. Evidence suggests that a flowable may be more effective than the combination of a porcine gelatin sponge with thrombin. 18, 19 Preparation of a flowable product requires reconstitution of the thrombin which must then be mixed with the absorbable gelatin particles. Thus, about 3 minutes are required for operating room staff to get the material ready prior to use. 20, 21 The flowables are easy to apply and are extruded from a syringe much like a tooth paste with a thickened consistency that allows the hemostat to stay in place at the site of bleeding. Because the products contain thrombin without fibrinogen, they require direct contact with blood as a fibrinogen source for conversion into fibrin. Pressure may be rapidly placed directly onto the flowable at the bleeding site by the surgeon using a moist saline (nonbloody) gauze or pad for a period of 2 minutes. Removal of the gauze or pad avoids clot disruption as the hemostat does not stick to the nonbloody saline-soaked gauze or pad which does not contain fibrinogen. The cost of flowables is higher, although some cost savings may be possible by using the porcine gelatin 21 with a separate stand-alone thrombin as opposed to the bovine gelatin and human pooled plasma thrombin provided by the manufacturer in a single kit. 20 If this cost-saving strategy is used, it is necessary to carefully choose the proper volume of stand-alone thrombin to mix with porcine gelatin to get the desired consistency (not too thick and cakey nor too thin and watery) and to instruct the operating room personnel in a method to reliably reproduce the mixture in all subsequent preparations. This careful effort is necessary to avoid inconsistency that can decrease effectiveness and satisfaction with a flowable hemostat.
The final category among the topical hemostats is fibrin sealant. This material has a unique, powerful, and sometimes confusing role because it has separate FDA approvals as a hemostat, sealant, and adhesive. Fibrin sealant consists of 2 components. It contains concentrated fibrinogen and thrombin which on mixing create a fibrin clot. The concentration of fibrinogen is proportional to clot strength whereas the concentration of thrombin is proportional to the rate of clot formation. Fibrin sealant works by increasing the rate of blood clot formation by providing higher concentrations of both fibrinogen and thrombin at a bleeding site than would normally occur in blood. There are 3 classes in this category ( Figure 2 ). These are pooled human plasma, individual human plasma with bovine collagen and bovine thrombin, and individual human plasma alone. The individual manufacture's products in each class within the fibrin sealant category have been previously presented in detail. 1 The safety concerns associated with fibrin sealant include those previously discussed including viral or prion disease transmission with pooled human plasma derivatives; antibody formation with bovine thrombin and swelling with bovine collagen; and the need for an intact native coagulation system and avoidance of any type of anticoagulant with individual human plasma ( Figure 3 ). One of the pooled human plasma products (Tisseel, Baxter, Westlake Village, California) contains synthetic aprotinin that can also be a potential source of allergic reactions. 22 Fibrin sealant is effective for the control of local as well as diffuse bleeding as it can be applied locally using a syringe-like applicator or sprayed over a larger area using a gas-driven device. Although the fibrin sealants were originally approved for specific individual bleeding indications, one of the products (Evicel, Johnson and Johnson, Somerville, New Jersey) has now been approved by the FDA with a broad label for broad surgical hemostasis. 23 The concerns raised clinically about fibrin sealant usability are mainly associated with the difficulty of reconstitution by hospital staff and a potential learning curve for surgeons with respect to the techniques of application. 24 The available pooled human plasma fibrin sealants may require thawing or mixing and the individual human plasma products require processing the patients own blood. Fibrin sealant products are among the more costly topical hemostatic materials.
Sealants
The materials approved for use as sealants are divided into 3 categories ( Figure 4 ): fibrin sealant; polyethylene glycol (PEG) polymer; and albumin with glutaraldehyde. The sealants work by forming a barrier that is impervious to the flow of most liquids.
The fibrin sealant category has already been discussed under the hemostat group. Additional comments will be provided here with respect to the role of fibrin sealant as a sealer ( Figure 5 ). It should be noted that only 1 fibrin sealant product which is in the pooled human plasma class has an on label approval as a sealant.
The product is approved to seal the colon at the time of colostomy closure 22 and it (Tisseel, Baxter, Westlake Village, California) has been previously presented in detail. 1 In addition, the safety profiles of the fibrin sealant category with respect to pooled human plasma-derived materials and the operating room staff preparation complexities associated with it as well as its relatively expensive cost have already been reviewed under the section on hemostats. Fibrin sealant is a moderate strength sealer ( Figure 5 ) and is most effective when it is applied by the surgeon to as dry a field as possible. 22 This is particularly important when applied to the normally moist serosal surface of the outer bowel wall or parenchymal tissues of abdominal viscera.
The PEG polymer category has 2 classes of materials: the first is 2 PEGs together; and the second is a PEG with trilysine amine (Figure 4 ). The individual manufacture's products in the 2 classes within the PEG polymer category have been previously presented in detail. 1 This category consists of synthetic materials and the major safety risk ( Figure 5 ) is swelling 25, 26 which varies from 400% (Coseal, Baxter, Fremont, California) down to 50% (Duraseal, Covidien, Mansfield, Massachusetts). The products are approved for vascular sealing to prevent blood loss and sealing of the dura to prevent CSF loss. They are moderately strong. The rate of immediate vascular sealing was more than doubled using the 2 PEG polymer 25 as compared to the use of a hemostat 25 and dural sealing was achieved 98% of the time using the single PEG with trilysine amine sealant. 26 The efficacy of both types of PEG polymers is improved by applying to a dry field and by allowing an adequate time (60 seconds) for polymerization. The PEG polymer category of products is moderately easy to prepare with time required to reconstitute the powdered PEGs and to assemble the provided applicators. Application is straightforward with manual spray devices. The dural sealant also uses Federal Food, Drug, & Cosmetic Act (FD&C) blue No 1 dye to provide a blue color that assists with accurate placement of the sealant. This category is relatively more expensive.
The final category of sealants consists of albumin and glutaraldehyde. The generic class can be described as bovine serum albumin cross linked using 10% glutaraldehyde ( Figure 4 ). The single manufacture's product in this class has been previously presented in detail. 1 The major safety concerns ( Figure 5 ) associated with the use of this category relate to the potential for tissue necrosis and adhesive embolism. Because the material contains glutaraldehyde, it is possible to cause significant nerve or muscle necrotic injury using this sealant. [27] [28] [29] Adhesive embolism, 30 limitation of aortic growth, 31 and pseudoaneurysm 27 formation have also been reported with this type of material. This product is a strong tissue sealant, which has been approved for sealing of large blood vessel anastomoses and is also indicated as an adhesive in aortic dissection for reattaching the layers of the aorta. 27, 32, 33 The sealant is quickly prepared by operating room personnel as it comes prepackaged in applicator syringes and is applied by the surgeon after priming of the applicator. This category is relatively more expensive.
Adhesives
The commercial products approved as adhesives can be divided into 3 categories ( Figure 6 ): cyanoacrylate; albumin and glutaraldehyde; and fibrin sealant. They vary significantly in their functional strength and surgical indications. However, each is designed to glue 1 type of tissue to another.
The cyanoacrylates are approved to hold the skin edges together and may also function as a barrier against bacterial penetration. These materials are for external use only. The cyanoacrylate category can be further subdivided into 2 generic classes either octyl or butyl cyaonacrylate based on the chemical structure of these synthetic compounds. The individual manufacture's products in each class within the cyanoacrylate category have been previously presented in detail. 1 This category of adhesives is relatively safe (Figure 7 ) as long as they are reserved for external use, and care is used to avoid getting this strong adhesive in unintended areas. Foreign body reaction has been reported 34 particularly if the product gets into subcutaneous tissues. 35 They can create a sensation of warmth on exothermic polymerization that may be interpreted by some patients as a painful stimulus. These materials are very strong adhesives, but their strength as a skin closure device is limited by the strength of the superficial layers of the dermis to which they are applied. Because the superficial dermis is always in the process of exfoliation and can tear away from deeper dermis, the role of this adhesive in providing a sole method of skin closure is limited. Hence, the products are approved as adjuncts and should be used with some form of deeper dermal sutures. Some recent data suggests superiority of octyl over butyl cyanoacrylate in terms of wound burst strength and flexibility. 36 Cyanoacrylates are immediately available for use in easily stored containers with integrated applicators. They are easily applied by surgeons, but their viscosity varies with each product with some being higher (Dermabond High Viscosity, Johnson and Johnson, Somerville, New Jersey) than others. Care should be used to avoid the flow of these adhesives onto sensitive-dependent structures such as the eye. They are relatively inexpensive.
The albumin and glutaraldehyde category has 1 single class of product. Bovine serum albumin with 10% glutaraldehyde ( Figure 6 ) has already been discussed in the section on sealants. The single manufacture's product in this class has been previously presented in detail. 1 It is included here as an adhesive because it is approved for attachment of the intimal and adventitial layers of the aorta during the repair of aortic dissection. 27 In comparison to other adhesives (Figure 7) , it may be associated with tissue injury, emboli, and pseudoaneurysm formation. This adhesive is strong as well as moderately easy to use and relatively expensive.
The final category under the adhesives is fibrin sealant. Only the pooled human plasma generic class of fibrin sealant has a recently approved product for use as an adhesive ( Figure 6 ). This new product (Artiss, Baxter, Westlake Village, California) is approved for the attachment of skin grafts to underlying wound bed at the time of burn graft surgery and can replace staples in this indication. The product's safety, efficacy, usability, and cost are similar to the manufacturer's previously approved fibrin sealant product (Tisseel, Baxter, Westlake Village, California) which has been reviewed in the past in detail. 1 One significant difference is that the new adhesive product 37 contains a much lower concentration of thrombin (5 IU/mL), which allows the fibrin sealant to polymerize more slowly. The thrombin concentration in fibrin sealant influences the rate of conversion of fibrinogen into fibrin. The lower thrombin concentration results in a longer 60-second polymerization time, which allows for a skin graft to be properly placed and adjusted prior to adhesive fixation. In comparison to other adhesives (Figure 7) , this material is of moderate strength, may be more complex to prepare and use, and is relatively expensive.
Suggestions
Authors specific suggestions are provided in the following sections for use of topical hemostats, sealants, and adhesives, and these are summarized in Figure 8 .
Mechanical Hemostats
These materials are desirable because of their ease of storage, preparation, and application as well as their relatively lower cost. However, the operator should not be fooled into thinking that their proper use is automatic. Mechanical hemostats are often applied dry to a wet field and are then removed when bleeding has ceased and the field is dry. This sequence is actually similar to that used by surgeons when using wet to dry dressings to debride infected fibrinous tissue or necrotic wounds. This reliable process assures that removal of the dry dressing will achieve wound debridement and removal of underlying undesirable debris. Unfortunately, this same process means that removal of a mechanical agent after achieving hemostasis without wetting it will similarly result in removal and debridement of underlying clot as well as a resumption of bleeding. Thus, it is important to removing mechanical agents to wet them prior to removal to leave intact clot behind and achieve maximum benefit. This wetting technique may be achieved by using a salinefilled syringe with a blunt nose cannula to irrigate precisely at the interface between the mechanical agent and the clot as the mechanical agent is being removed. 
Active Hemostats
These agents are most frequently used in liquid form which is excellent for product delivery over large areas with diffuse oozing of blood. For localized bleeding, application of these liquids may be challenging as the liquid tends to be washed away by active bleeding or drip away due to the effects of gravity and the topography of the wound. In addition, it may be difficult to combine the use of pressure, a mainstay of surgical hemostasis with a liquid. Thus, the lesson to applying these agents for more active local bleeding is delivery in combination with one of the mechanical agents, an absorbable gelatin sponge or powder, or a soaked operating room gauze or laparotomy pad. When using an absorbable sponge in conjunction with thrombin, it is important that the sponge not be sopping wet but rather be gently squeezed prior to use to remove excess thrombin. The sponge should be moist with thrombin but still able to absorb some blood into its interstices to allow both the mechanical action of the sponge and the active clotting mechanism of the thrombin to come into effect. In this setting, removal of the absorbable sponge may sometimes be difficult as it becomes incorporated into the formed clot and removal may cause significant clot disruption. Adding saline to the field after the bleeding has stopped prior to any attempts at removal of the sponge, gauze, or pad may facilitate the maintenance of hemostasis. Combining thrombin with an absorbable gelatin powder may be useful as it results in puttylike material that can be used to caulk a bleeding site. Because the acid environment of oxidized regenerated cellulose may inactivate thrombin, prolonged exposure of these 2 agents prior to actual use should be avoided.
Flowable Hemostats
The flowables combine many of the best characteristics of the mechanical and active agents providing a hemostat that is capable of getting into the depths of a wound, adjusting to wound topography, providing a mechanical barrier, and actively clotting blood. Therefore, it may be helpful to assure that the product is carefully applied down into lacerations and irregular surfaces by gentle spreading and not just applied to the top layers of an irregular wound where blood may be appearing but may not be originating. These agents can easily be combined with pressure because their cream of wheat-like consistency can be compressed with a saline-soaked gauze or laparotomy pad for several minutes to allow for successful clot formation. It is important to remember that the gauze or pad should be soaked with saline and not any blood. If the gauze or pad contains blood, the blood will react with the flowable forming a clot and the sticky clot will be dislodged when the gauze or pad is removed. Additional flowables can be reapplied with the blunt nosed applicator tip that needs to be positioned in such away that the new material is burrowed under previously applied product so that the new material comes into direct contact with blood that provides the fibrinogen necessary for the flowable to create clot. Any not clotted flowable matrix can be removed with a stream of saline used in combination with a discard sucker once hemostasis has been achieved.
Fibrin Sealant
As a 2-component liquid material containing fibrinogen and thrombin, fibrin sealant also may benefit by combination with an absorbable gelatin sponge to assure delivery of the liquids to a local site of active bleeding and allow the fibrin sealant to be combined with the significantly beneficial effects of manual pressure. In this case, however, because the agent contains both concentrated fibrinogen and thrombin, the sponge will not be removable and will need to be left in place as it is glued into the wound by a fibrin sealant clot. When using fibrin sealant to prevent seroma formation between flaps, it is important to assure rapid sealing of the tissues and contact of the flaps to be glued together. This adherence can be facilitated by placing a closing lattice work of sutures prior to applying the fibrin sealant and bringing the flaps into apposition with pressure application immediately after sealant placement so that the flaps are in contact while the sealant is still polymerizing. Disruption of the formed flap adhesions should then be carefully avoided when handling the wound. Disruption after the placement of fibrin sealant could actually make seroma accumulation worse than without any fibrin sealant application. In this setting, the disrupted fully polymerized fibrin sealant will function as an antiadhesive, preventing flap adherence and thereby maintaining a potential space for seroma formation. When using fibrin sealant as an adhesive to apply skin grafts, avoid too thick a layer of sealant, which can prevent diffusion of nutrients to the graft from the underlying muscle bed. In our hands, fibrin sealant has been a very powerful agent because it is the only material approved by the FDA as a hemostat, sealant, and adhesive, but it does require some patience and persistence as the surgeon gets used to its many characteristics.
Polyethylene Glycol Polymers
The available materials can be used most effectively by assuring that the tissues to be sealed are as dry and free of blood or fluid as possible. These agents, themselves, are initially applied as liquids which polymerize quickly but may still tend to drip away from the intended site of application unless the effects of gravity and topography are anticipated in advance by the surgeon.
Albumin and Glutaraldehyde
This is a very strong sealant and adhesive that needs to be applied carefully and as sparingly as possible. Critical zones of the operative field should be protected by walling off with removable sponges or pads to avoid injuring delicate tissues such as nerves or occluding blood vessels such as coronary arteries. Using large volumes of the material should be avoided and may increase the potential complications of its use including muscle necrosis, embolus, and delayed pseudoaneurysm formation. The applicators need to be primed by a small amount of product release outside of the field to get the process of albumin cross-linking by glutaraldehyde initiated. Finally, a discard sucker should always be present to immediately remove any unwanted liquid material before it polymerizes and becomes adherent.
Cyanoacrylates
These materials are also very strong adhesives approved at the moment only for topical external use. Skin edges should be kept approximated for at least 30 seconds following application to allow for complete curing of the cyanoacrylate. Multiple layers should be used for octyl cyanocrylates whereas butyl cyanoacrylates should used more sparingly. Cyanoacrylates need to be applied after careful planning and positioning to avoid run off of the liquid cyanoacylate to unwanted locations particularly if being used on the face. They should be used as an adjunct to wound closure in combination with deep dermal sutures and not as the only means of closing wounds as dehiscence is possible. Their ability to function as a temporary barrier capable of protecting wounds from serous or lymphatic fluid leakage and from external sources of bacteria is also a desirable characteristic that may be useful in reducing wound infection rates.
Recent Literature Reports of Specialty Specific Safety, Efficacy, and Application Techniques
Selected recent reports on the use of hemostats, sealants, and adhesives in specific surgical specialties are provided below.
Abdominal Surgery
Several recent studies evaluated the comparative safety and efficacy of topical agents in animal models of abdominal surgery. The safety of multiple different hemostats, sealants, and adhesive were evaluated in a laboratory rat cecal adhesion model. 38 Materials evaluated included oxidized regenerated cellulose, polysaccharide spheres, bovine collagen with human pooled plasma thrombin, human pooled plasma fibrin sealant, 2 PEG polymer hydrogel, and bovine albumin and glutaraldehyde. Adhesion formation was least with polysaccharide spheres and PEG polymer. Adhesion formation as well as tissue necrosis was greatest using bovine albumin and glutaraldehyde. In another report, a numerical bleeding score analysis using a heparinized pig model of liver biopsy demonstrated the statistically significant hemostatic superiority of porcine gelatin sponge with human thrombin as compared to porcine gelatin sponge and saline at multiple time points up to 10 minutes after treatment. 39 A third model of grade IV-V combined liver and spleen lacerations using 10 heparinized pigs with hemorrhagic shock demonstrated that bovine gelatin and thrombin (approximately 1.4 mL/pig) was effective at achieving hemostasis in all animals and that clot integration was present at 48 hours on histologic examination. 40 The use of surgical adhesives has been described in additional abdominal surgical indications. Fibrin sealant use was recently investigated in humans for mesh fixation during inguinal hernia repair using both laparoscopic extraperitoneal 41 and intraperitoneal approaches. 42 It was found to be less painful than staple fixation. 42, 43 One laboratory animal study supports the use of large pore, light-weight polypropylene meshes for the best attachment strength when using fibrin sealant for fixation 44 and another suggests that it may even be possible to repair hiatal hernias using fibrin sealant mesh fixation. 45 Bovine albumin and glutaraldehyde in combination with polypropylene mesh has been used successfully for fundoplication and crural reinforcement in a series of 35 patients undergoing laparoscopic repair of intrathoracic stomach. 46 There were 3 intraoperative conversions, 1 intraoperative complication, and 3 postoperative complications. Follow-up was possible in 21 of 25 eligible patients at 1 year or more after the procedure and the recurrence rate was 9.5% (2 of 21). Finally, the use of cyanoacrylates for wound closure is summarized in a recent review article. 47 Application of tissue sealants and adhesives to seal pancreatic resections to prevent pancreatic fistulas remains controversial as noted in a recent review. 48 A new clinical study suggested that the rate of fistula formation actually may increase following the use of bovine albumin and glutaraldehyde at pancreaticojejunostomies and distal pancreatectomy resections. 49 A laboratory study suggested that significant pancreatic tissue reactions occur at pancreaticojejunostomies using cyanoacrylates while lesser pathologic changes occur using fibrin sealants or bovine albumin with glutaraldehyde. 50 
Breast Surgery
Safety and efficacy reports on topical agents in breast surgery have provided valuable new information. A case report in the radiologic literature suggested that malignant appearing microcalcifications on a mammogram which were actually benign may appear following the use of a flowable consisting of bovine gelatin and human pooled plasma thrombin at a previous lumpectomy site. 51 In a randomized, prospective, controlled study of 30 patients, fibrin sealant mixed with 3.5% lidocaine was found to statistically significantly reduce pain following subpectoral breast augmentation procedures. 52 The use of 2 PEG polymer hydrogel or albumin and glutaraldehyde did not reduce seroma fluid drainage or time to drain removal following axillary dissection procedures for treatment of breast cancer in a randomized, prospective, controlled trial of 75 patients. 53 Use of these sealants resulted in foreign body tissue reaction with the need for surgical intervention in some patients. Another consecutive case study of using albumin and glutaraldehyde in breast cancer surgery found a statistically significant beneficial effect on the frequency and volume of aspirated seromas during the recovery period in 33 treated patients as compared to 32 control patients. 54 Repeated aspirations in follow-up were needed in 21.2% of treated patients and 37.5% of control patients.
Burn Surgery
Recombinant human thrombin was found to achieve hemostasis and facilitate the application of partial or full thickness skin grafts in burn wound resection surgery in a multisite, singlearm, open-label study of 72 patients. 55 Hemostasis was achieved after conventional control of point source bleeding using spray application of thrombin within 20 minutes in 91.5% of patients. The graft failure rate was 6%.
Cardiac Surgery
Several new reports on the effectiveness of topical hemostats during cardiac surgical operations have appeared. A prospective, randomized, multicenter study comparing either human pooled plasma thrombin or bovine thrombin in combination with porcine gelatin sponge in 305 patients revealed no difference in efficacy between the 2 forms of thrombin in cardiac, neuro, or general surgical procedures. 56 Efficacy was based on those patients achieving hemostasis at 10 minutes. Cessation of bleeding with either form of thrombin combined with porcine gelatin sponge occurred in over 70% of patients in 3 minutes or less. Another recent prospective, randomized, nonblinded study found significant benefit to using a flowable hemostat at active bleeding sites during cardiac surgical operations compared to control mechanical hemostats. 57 All hemostats were applied according to manufacturer's instructions and specifically following protamine reversal. In this same study, the flowable agent containing bovine collagen and bovine thrombin was compared to control application of either porcine gelatin or oxidized regenerated cellulose alone. Statistically significant reductions in achievement of hemostasis by more than 30%, time to hemostasis by more than 3 minutes, overall postoperative bleeding by more than 150 mL, and incidence of blood transfusions by more than 18% were noted compared to the control agents. The significant improvement in time to hemostasis was also confirmed in patients undergoing cardiac surgical procedures using systemic hypothermia. In another human study, statistically significant data supporting a new method of application of commercial human pooled plasma fibrin sealant in aortic dissection operations suggest that a ''rub-and-spray'' method may be particularly effective. 58 The technique involves first rubbing fibrinogen into needle holes followed by application of spray thrombin with 3 minutes of polymerization time prior to reperfusion. Using this method, statistically significant reductions were found in the 10 treated fibrin sealant patients as compared to the 10 control patients receiving no fibrin sealant in the number of bleeding needle holes, proportion of proximal and distal bleeding needle holes, duration of bleeding, and overall blood loss.
The use of sealants to prevent postpericardiotomy adhesions has remained an area of investigation. A multicenter, prospective, observational study evaluating 36 pediatric patients undergoing staged reoperative congenital cardiac surgery more than 3 months after the initial procedure evaluated a hydrogel polymer consisting of 2 PEGs to seal the anterior mediastinum. 59 Results revealed a reduction in adhesions, although 5 patients sustained serious adverse events potentially related to the sealant. However, the use of a PEG and trilysine amine polymer hydrogel was investigated in a controlled 7 pig study and was found not to produce any reductions in adhesion formation. 60 In this study, adhesions were measured using a mathematical adhesion score at 6 weeks postpericardiotomy which was originally performed with instillation of intrapericardial blood to facilitate the creation of adhesions.
Several investigations evaluated the use of topical agents as adhesives in cardiac surgery. Using a rodent model of chronic ischemic cardiomyopathy, intramyocardial injection of fibrin sealant was found to stop negative remodeling, enhance angiogenesis, and reduce infarct size potentially serving as a basis for treatment of heart failure. 61 The use of octyl cyanoacrylate was evaluated in a prospective, randomized, controlled trial of 106 patients comparing skin closure following saphenous vein harvesting for coronary artery bypass grafting using the bridging technique. 62 Statistically significant benefits were found for the skin closures using octyl cyanoacrylate versus subcuticular sutures in time required to close the leg incisions, cosmetic appearance at 1 and 6 weeks, and overall patient satisfaction. In another study designed to gain incite into the use of adhesives in aortic root replacement, the mechanical properties of fibrin sealants, PEG polymer, and albumin and glutaraldehyde were compared. 63 Albumin and glutaraldehyde was found to be significantly stiffer than the other materials as well as stiffer than aortic root grafts and native aortic tissue raising the possibility that it might contribute to anastomotic stricture and restriction of physiologic root dilation. Additional potential complications associated with the use of albumin and glutaraldehyde in cardiac operations have been recently reported including valve dysfunction 64 and inferior vena caval compression masquerading as pericardial tamponade. 65 
Head and Neck Surgery
The use of topical hemostats has been studied lately in head and neck operations. In a randomized, prospective, nonblinded study, 155 consecutive total thyroidectomy operations were performed with a flowable or oxidized regenerated cellulose to achieve hemostasis. 66 The flowable group using bovine gelatin and thrombin had statistically significant reductions in operative time of 17 minutes as well as time to drain removal and hospital discharge. In another report, a flowable consisting of porcine gelatin and bovine thrombin was used in a multicenter, prospective, single-arm study to evaluate its hemostatic effectiveness in 30 patients undergoing endoscopic sinus surgery. 67 Hemostasis was achieved in 96.7% of patients within 10 minutes with a reported median time to hemostasis of 61 seconds. In a laboratory study using a rabbit model of nasal mucosal injury of the maxillary sinus, polysaccharide spheres were compared with a flowable consisting of bovine gelatin and human pooled plasma thrombin. 68 Healing at 2 weeks was evaluated by a blinded pathologist. Sinuses treated with bovine gelatin and human pooled plasma thrombin showed extensive loss of cilia, inflammation, and fibrosis compared to the control untreated sides. The polysaccharide sphere treated sinuses did not exhibit these pathologic changes.
The use of topical adhesive has also been recently investigated in head and neck procedures. In a randomized, controlled, prospective, single-center study of 146 patients, fibrin sealant was evaluated as a method of achieving hemostasis as well as for sealing the septum and flaps associated with septoplasy and conchotomy. 69 Both treatment groups used fibrin sealant, but 1 group had no sutures applied to the septum or flaps. Results were similar in both groups, suggesting that fibrin sealant use may be able to eliminate the need for transeptal suturing. A series of 80 patients (20 thyroidectomies, 13 submandibular gland resections, 9 parotidectomies, 6 neck dissections in conjunction with other surgical procedures, 1 lateral rhinotomy, 1 thyroglossal cyst resection, and 30 open neck biopsies) were evaluated to compare wound closure using butyl cyanoacrylate to standard closure with sutures. 70 The cyanoacrylate method was faster by the large factor of 15 and appearance was judged satisfactory with no wound complications in either the treated or control groups. Patients were similar with respect to age, gender, and incision length. Another prospective, consecutive patient trial in 100 participants supported the long-term safety and efficacy of butyl cyanoacrylate for closing parotidectomy incisions. 71 The study included over 7 years of follow-up and the incidence of hypertrophic scars and keliods was 8% and 9%, respectively, in the butyl cyanoacrylate patients which is thought comparable to the rate using suture technique for wound closure.
The use of topical hemostats in oral surgery in patients with compromised hemostasis due to medications or illness such as von Willebrand diseases or hemophilia A has been recently reviewed, and these agents were found to allow for effective wound management in many cases. 72 
Neurosurgery and Orthopedic Surgery
Meticulous hemostasis has remained a critical issue in neurosurgical procedures and topical hemostats have been a useful adjunct. A comparative rat model of neurosurgery with approximately 40 animals in each group was used to test efficacy and safety of bovine collagen, oxidized regenerated cellulose, polysaccharide spheres, and bovine gelatin combined with human pooled plasma thrombin. 73 All 4 stopped bleeding within 1 minute but only oxidized regenerated cellulose and polysaccharide spheres avoided granuloma formation on pathologic examination. A minimally invasive method of treating spontaneous supratentorial intracerebral hemorrhage has been described using a flowable hemostat. 74 After a linear incision and 3 cm craniotomy, hematomas were evacuated and bovine gelatin with pooled plasma thrombin was placed in 31 patients without vascular anomalies or bleeding disorders. Hemostasis was successfully achieved in all patients and only 1 patient required reexploration. The benefits of this technique may include a reduction in surrounding brain damage. In a rat model of back surgery, topical treatment of 8 animals with bovine gelatin and human pooled plasma thrombin after laminectomy was compared to no application after laminectomy in 8 control animals. 75 The treated rats had significantly less epidural fibrosis as well as less fibroblast and inflammatory cell density.
Reports of complications using flowables in patients have also appeared in the spine surgery literature. A case report of right heart failure and disseminated intravascular coagulation following the use of a flowable containing porcine gelatin and bovine thrombin to achieve hemostasis in a posterior fusion operation as treatment for scoliosis has recently been published. 76 The case suggested that thrombin may have entered the venous circulation causing fatal thrombosis. In addition, a single report of 2 cases of spinal compression secondary to the use of flowable of bovine gelatin and human pooled plasma thrombin at the time of pedicle screw insertion due to inadvertent extravasation of the hemostatic matrix into the spinal canal was reported. 77 In both instances of epidural spinal cord compression, neurologic symptoms appeared and the patients required reexploration for removal of the extravasated material. Fortunately, both patients eventually had complete recoveries with resolution of all symptoms.
The use of sealants to prevent CSF leakage has gained wider use in neurosurgery. A report of cervicomedullary compression secondary to an expanding mass consisting of a PEG and trilysine amine polymer hydrogel and gelatin sponge has been reported. 78 The materials were used for dural sealing in a case of posterior fossa decompression and dural augmentation for Chiari malformation type I. The case emphasized the fact that both of these materials swell and should not be used in critical confined spaces. A second report of a complication associated with this same polymer hydrogel suggested that the material may migrate after application and caused cauda equina compression following the performance of a laminotomy and discectomy. 79 Both movement and swelling were documented on sequential imaging studies with operative removal on postoperative day 10, confirming proximal migration.
In a prospective single-armed study using retrospective fibrin sealant controls, PEG and trilysine amine polymer hydrogel application to seal the dural incision was found to be statistically significantly superior to fibrin sealant at preventing CSF leaks following posterior fossa craniotomy or craniectomy. 80 The leak rate was 2% (2 of 100) for the polymer and 10% (10 of 100) for fibrin sealant. In another report, the technique of using a ''gasket-seal'' consisting of autologous fascia lata around a bone buttress in combination with PEG and trilysine amine polymer hydrogel to seal the anterior cranial base in transnasal minimal access endoscopic procedures has been described. 81 There were no cerebrospinal leaks noted in any patients including no leakage from lumbar drains placed intraoperatively in 5 patients using this method.
In an orthopedic study, a long-term follow-up after an average time of more than 12 years was performed in patients undergoing Achilles tendon surgical repair using sutures in 11 patients or fibrin sealant in 31 patients. 82 The results revealed superior function, equal strength, and fewer complications using fibrin sealant tendon fixation.
Obstetric and Gyneclogic Surgery
The use of flowable agents has been evaluated in multiple gynecologic procedures. A new method of performing laparoscopic ovarian cystectomy has been described. 83 Hemostasis of the ovary after stripping of the cyst was performed using a flowable of bovine gelatin and pooled plasma thrombin without the need for sutures or electroacautery. The method may have reduced thermal and inflammatory injury to the remaining ovarian tissue. Another study of laparoscopic stripping of ovarian endometriomas compared the use of bovine gelatin and pooled plasma thrombin in 8 treated cases to 12 control patients treated with bipolar cautery for achieving hemostasis. 84 The times to cessation of bleeding were similar. This method of achieving hemostasis provided a way to potentially reduce follicular damage associated with the use of electrocautery. In a third report, a randomized, controlled, prospective, singlecenter trial, on the use of bovine gelatin and thrombin for bleeding from uterine tissue was described in 50 women undergoing abdominal myomectomy. 85 Large reductions in intraoperative and postoperative bleeding, use of transfusions, and hospital stay were found.
The degree of posterior uterine adhesions was significantly reduced in 71 patients entered into a prospective randomized trial using 2 PEG polymer hydrogel to seal uterine tissues following myomectomy at the time of laparoscopy or laparotomy. 86 Second look procedures at 8 to 10 weeks revealed the reductions. No intra-abdominal or wound infections occurred and the numerical occurrence of adverse events was larger in the control group.
Ophthalmologic Surgery
Fibrin sealant has been used more frequently in ophthalmology as is discussed in a review describing the use of this material. 87 Fibrin sealant has been used to seal tissues or suture lines, fix tissues or devices in place, and to completely replace sutures in a variety of applications. Cyanoacrylates have also been used as adhesives for ophthalmologic procedures. Octyl cyanoacrylate was applied to the upper eyelid for progressive myophathic blepharoptosis in 10 consecutive patients to increase the depth of the upper lid crease. 88 The placement of hyperdry amniotic membrane patches using octyl cyanoacrylate for the treatment of corneal perforations or glaucoma bleb leaks was reported to be successful in 5 patients. 89 
Plastic Surgery
Recent reports of the successful use of cyanoacrylates in plastic surgery included a randomized, prospective trial of the use of octyl cyanoacrylate for wound closure following bilateral reduction mammoplasty with the patients serving as their own controls. 90 In this study, one side was closed with adhesive and the other with sutures. Statistically significant benefits in terms of comfort and appearance were found at 6 weeks and 6 months. In a retrospective study of unilateral cleft lip repair comparing closure using octyl cyanoacrylate in 186 patients with steri-strips in 121 patients, similar hypertrophic scar rates were found. 91 There were no infections or need for scar revisions in the cyanoacrylate group which was performed in the most recent time period. In this study, historical controls using steri-strip skin closure had an infection rate of 4% and a scar revision rate of 6% in the earlier time period. A series of 8 female patients had high-viscosity octyl cyanoacrylate used for skin closure following blepharoplasty. 92 Application of adhesive was performed with temporary sutures to facilitate skin edge approximation and placement of the agent. The sutures were removed immediately after cyanoacrylate polymerization. Closure time was 6.9 minutes, aesthetic results were judged to be very good to excellent, and no complications occurred. There was a minor dehiscence rate of 12.5% (2 eyelids).
Thoracic Surgery
The use of topical agents to reduce air leaks following lung resection continued to be evaluated. In a randomized, prospective, and blinded study, air leak in lung volume reduction procedures was reduced in frequency by more than 25% and in duration by 3 days using an autoglous fibrin sealant for reinforcement of staple lines. 93 A specific application technique was used with the fibrin sealant being placed on the deflated lung staple line and extending outward 1 cm laterally at each side of the staple line. In another study, a polymer consisting of 2 PEGs was used as a lung sealant to reinforce leaking lung staple lines following resection in a randomized, prospective controlled trial. 94 The sealant decreased the proportion of patients with air leaks versus control patients at 24 hours to 19.6% versus 40.6% and at 48 hours to 23.5% versus 41.6%. The duration of air leaks was also statistically significantly reduced in the sealant treated group. Albumin and glutaraldehyde adhesive has been reported as being capable of creating a successful seal within 24 hours in a series of 3 patients with postoperative brochopleural fistulas using a brochoscopic approach for adhesive application. 95 
Urologic Surgery
The use of hemostats to achieve hemostasis following partial nephrectomy has been evaluated in several studies. A continuous series of 35 patients undergoing laparoscopic partial nephrectomy for renal tumors by a single surgeon at one institution was used to investigate 2 forms of flowable hemostats, bovine gelatin or porcine gelatin, both combined with thrombin. 96 No differences in efficacy or safety were found. In another report of 20 consecutive patients operated upon at a single center using a robotic approach to perform a laparoscopic partial nephrectomy for the treatment of tumors less than 7 cm described the successful use of bovine gelatin and thrombin to facilitate hemostasis prior to capsular closure with running suture and surgical clips. 97 There were no bleeding complications with follow-up of 1 year. Lastly, a laboratory study in pigs has demonstrated the feasibility of sutureless laparoscopic heminephrectomy in 5 pigs. 98 Hemostasis was achieved using an argon beam coagulator as well as flowable of bovine gelatin and human pooled plasma thrombin. Security at the transection site was achieved using a sandwich of decellularized bovine pericardium and bovine albumin and glutaraldehyde. No urine leaks were demonstrated on pyelography in the 4 week follow-up period.
Another study of challenging renal trauma in 180 heparinized rats revealed that gelatin in the form of a sponge or matrix with or without thrombin or recombinant factor VIIa achieved hemostasis 100% of the time, whereas polysaccharide spheres with or without recombinant factor VIIa achieved hemostasis 25% of the time. 99 Thrombin and factor VIIa alone did not achieve hemostasis in this model. However, using the efficacious combination of gelatin even with the addition of thrombin or recombinant factor VIIa resulted in re-bleeding within 60 minutes in 34% of cases, suggesting that additional agents may be needed to achieve long lasting hemostasis in this setting.
Vascular Surgery
A recent publication analyzed hemostats in a vascular subset consisting of 164 patients from a larger randomized, prospective, multicenter, double blind study. 100 The article compared bovine thrombin and human recombinant thrombin. In peripheral vascular procedures as well as dialysis access operations, both forms of thrombin were equally effective in achieving hemostasis at 10 minutes. The recombinant thrombin was statistically significantly better at achieving hemostasis at 3 minutes than bovine thrombin, 55% versus 39%.
The treatment of groin pseudoaneurysm with ultrasoundguided injection of thrombin was recently reviewed and assessed. 101 The technique was judged to be safe, effective, and cost-beneficial as well as requiring only a brief learning curve. It was suggested that this method may be approaching standard of care.
Conclusions
The surgeons' desire for improved tools to facilitate the technical performance of operations continues to drive new research and development in the field of topical hemostats, sealants, and adhesives. This article has provided an update on new products; comparisons of categories of agents in terms of safety, efficacy, usability, and cost; suggestions for how these products may be best applied; and a specialty-specific review of the recent literature in this area. Choices of which materials to use as well as when and how to use them need to be made and the information contained here is intended to help with these decisions.
